Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics (NQ: SRPT )

123.50 +5.98 (+5.09%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,387,817
Open 117.53
Bid (Size) 120.00 (4)
Ask (Size) 126.44 (1)
Prev. Close 117.52
Today's Range 115.74 - 123.73
52wk Range 55.25 - 146.68
Shares Outstanding 93,148,652
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above
From Sarepta Therapeutics, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga

Performance

YTD
+28.37%
+28.37%
1 Month
-5.60%
-5.60%
3 Month
-2.05%
-2.05%
6 Month
+36.78%
+36.78%
1 Year
-6.01%
-6.01%

More News

Read More
A Glimpse Into The Expert Outlook On Sarepta Therapeutics Through 9 Analysts
Via Benzinga
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Via Investor's Business Daily
Exposures Product Safety
12 Analysts Have This To Say About Sarepta Therapeutics
Via Benzinga
What Analysts Are Saying About Sarepta Therapeutics Stock
Via Benzinga
Exit Strategy: 3 Overvalued Stocks to Sell Before They Deflate
Via InvestorPlace
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Sarepta Therapeutics Stock Is Rising Today
Via Benzinga
Topics Stocks
Exposures US Equities
Sarepta Downgraded As FDA Decision Date Approaches, Shares Up 50% Over Last Six Months
Via Benzinga
Exposures Product Safety
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
The 2030 Millionaire’s Club: 3 Biotech Stocks to Buy Now
Via InvestorPlace
Jim Cramer: This Industrial Stock Is Doing 'Very Well'; Here's His Take On Palantir
Via Benzinga
Why Dyne Therapeutics, With A 108% Run This Year, Just Catapulted Again
Via Investor's Business Daily
3 Biotech Stocks With the Potential to Make You an Overnight Millionaire
Via InvestorPlace
Exposures Product Safety
Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health
From Sarepta Therapeutics, Inc.
Via Business Wire
Apple, Kellanova And 3 Stocks To Watch Heading Into Thursday
Via Benzinga
SRPT Stock Earnings: Sarepta Therapeutics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Sarepta Therapeutics (SRPT) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
1 Top Growth Stock to Buy and Hold for 10 Years
Via The Motley Fool
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics Stock Shows Improved Technical Strength
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.